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ABSTRACT
Objective A predictable relation between genotype
and disease expression is needed in order to use genetic
testing for clinical decision-making in hypertrophic
cardiomyopathy (HCM). The primary aims of this study
were to examine the phenotypes associated with
sarcomere protein (SP) gene mutations and test the
hypothesis that variation in non-sarcomere genes
modiﬁes the phenotype.
Methods Unrelated and consecutive patients were
clinically evaluated and prospectively followed in a
specialist clinic. High-throughput sequencing was used
to analyse 41 genes implicated in inherited cardiac
conditions. Variants in SP and non-SP genes were tested
for associations with phenotype and survival.
Results 874 patients (49.6±15.4 years, 67.8% men)
were studied; likely disease-causing SP gene variants
were detected in 383 (43.8%). Patients with SP variants
were characterised by younger age and higher
prevalence of family history of HCM, family history of
sudden cardiac death, asymmetric septal hypertrophy,
greater maximum LV wall thickness (all p
values<0.0005) and an increased incidence of
cardiovascular death (p=0.012). Similar associations
were observed for individual SP genes. Patients with
ANK2 variants had greater maximum wall thickness
(p=0.0005). Associations at a lower level of signiﬁcance
were demonstrated with variation in other non-SP genes.
Conclusions Patients with HCM caused by rare SP
variants differ with respect to age at presentation, family
history of the disease, morphology and survival from
patients without SP variants. Novel associations for SP
genes are reported and, for the ﬁrst time, we
demonstrate possible inﬂuence of variation in non-SP
genes associated with other forms of cardiomyopathy
and arrhythmia syndromes on the clinical phenotype of
HCM.
INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is a
common autosomal dominant genetic trait asso-
ciated with sudden cardiac death (SCD) and pro-
gressive heart failure.1 2 Patients are routinely
offered genetic testing in order to provide them
with information about the likely impact of disease
on their lives and facilitate lifestyle and medical
interventions that improve prognosis.2 3 However,
for this strategy to succeed, there must be a predict-
able relation between speciﬁc genotypes and
disease expression.
In around 50% of cases, HCM is caused by
mutations in genes coding for sarcomere or
sarcomere-related genes.4 So far, the most com-
monly reported genotype–phenotype associations
are those that relate to the presence or absence of
sarcomere protein (SP) gene mutations rather than
mutations in speciﬁc genes.5 6 A number of studies
have suggested that some mutations are associated
with reduced survival, but these ﬁndings are incon-
sistent and fail to account for the often dramatic
variation in clinical phenotypes seen in individuals
with the same genetic variant.w1–w7 7 w8 8 w9 9 w10
w11 10 w12 11 w13 w14 12 13 w15–w18 14 w19 15 16
Several studies have examined the role of
common genetic variation on the expression of
sarcomere mutations using genome-wide associ-
ation studies or a candidate gene approach, but
most have failed to show any major effect on
disease expression.w20–w22 17 18 HCM cases (as well
as controls) also carry rare variants in genes coding
for desmosomal, ion-channel and other proteins
implicated in inherited heart disease19 but their
relevance to disease expression is unknown.
The hypothesis of this study is that rare variants
in sarcomere genes and also in non-sarcomere
genes implicated in other forms of inherited
cardiac disorders (for which sequence data are
available in our study) modify the clinical character-
istics and severity of HCM.
METHODS
Study population and design, clinical evaluation
and sample collection
The study was approved by the University College
London (UCL)/UCL Hospitals (UCLH) Joint
Research Ethics Committee. Before enrolment, all
patients provided written informed consent and
received genetic counselling in accordance with
international guidelines.3
An observational, retrospective, longitudinal
cohort study design was used. The study popula-
tion comprised unrelated and consecutively evalu-
ated patients with HCM referred to the Inherited
Cardiovascular Disease Unit at The Heart Hospital,
UCLH, London, UK. Clinical evaluation included a
personal and family history, physical examination,
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12 lead ECG, echocardiography, symptom limited upright exer-
cise testing with simultaneous respiratory gas analysis (cardio-
pulmonary exercise test) and ambulatory ECG monitoring as
previously described.20 HCM was diagnosed in probands when
the maximum left ventricular (LV) wall thickness (MLVWT) on
2D echocardiography measured 15 mm or more in at least one
myocardial segment or when MLVWTexceeded 2 SDs corrected
for age, size and gender in the absence of other diseases that
could explain the hypertrophy.21 In individuals with unequivo-
cal disease in a ﬁrst degree relative, diagnosis was made using
extended familial criteria for HCM.22 Ethnicity was self-
reported and classiﬁed using a modiﬁed National Health Service
ethnic categorisation. Patients were evaluated every 6–12
months or earlier if there was a clinical event. Initial evaluation
and follow-up data were collected prospectively and registered
in a relational database. The deﬁnitions of severe LV hyper-
trophy, family history of SCD, syncope, non-sustained ventricu-
lar tachycardia (NSVT) and abnormal blood pressure response
were as previously described.23
Targeted gene enrichment and high-throughput sequencing
Blood samples were collected at initial evaluation and DNA was
isolated from peripheral blood lymphocytes using standard
methods. The sequencing methodology has been reported in
detail previously.19 In summary, the protocol was designed to
screen 2.1 Mbp of genomic DNA sequence per patient, covering
coding, intronic and selected regulatory regions of 20 genes
known to be associated with HCM and dilated cardiomyopathy
(MYH7, MYBPC3, TNNT2, TNNI3, MYL2, MYL3, ACTC1,
TPM1, TNNC1, MYH6, CSRP3, DES, TCAP, PDLIM3, PLN,
LDB3, LMNA, VCL, RBM20 and TTN), 10 genes implicated in
arrhythmia syndromes/ion-channel disease (RYR2, KCNQ1,
KCNH2, SCN5A, KCNE1, KCNE2, ANK2, CASQ2, CAV3 and
KCNJ2), seven genes associated with arrhythmogenic right ven-
tricular cardiomyopathy (PKP2, DSC2, DSG2, JUP, DSP,
TMEM43 and TGFß3) and a further four candidate genes
(GJA1, PLEC, PNN and PKP4) which were not analysed in this
work.19 Analysis of titin (TTN) variants and their effect on
phenotype is ongoing and will be reported in a separate paper.
Bioinformatic analysis
Paired-end reads were aligned using Novoalign software
V.2.7.19 on the human reference genome build hg19. Duplicate
reads were ﬂagged using the Picard MarkDuplicate tool. Our
calling strategy followed closely the Genome Analysis Toolkit
(GATK) best practices as of January 2014. Brieﬂy, following
BAM ﬁle compression using the GATK ReduceReads module,24
multisample calling was performed on all probands jointly with
a set of 1492 unrelated whole exomes (UCL-exome consortium)
using the GATK Uniﬁed Genotyper.24 After GATK variant reca-
libration (separately for SNPs and indels), calls were annotated
using the ANNOVAR software (with the Ensembl gene deﬁni-
tions).w23 For all association tests, we ﬁltered variants for the
GATK recalibration PASS ﬁlter.
Candidate variants for further analysis were deﬁned using fre-
quency and predicted functional effect. For the functional ﬁlter,
exonic non-synonymous, loss-of-function and splice-site variants
were included. Sequence data were ﬁltered using a minor allele
frequency threshold of ≤0.2% based on the NHLBI exome
variant server data (computed through the ANNOVAR annota-
tions). To provide a more accurate estimate of variant frequency
in controls that is not affected by potential differences in calling
strategy in the NHLBI dataset, we randomly selected 25% of
the 1492 UCL-exome samples as an ‘external control set’ and
removed variants that appeared more than twice in these 372
‘external controls’. These samples were only used to deﬁne a
variant frequency and not included in the subsequent associ-
ation test, to avoid a previously noted statistical issue, where
variant frequency is deﬁned in the same set that is used for case
control testing.w24 Variants present in the dbSNP build 137
databasew25 and published in the literature were identiﬁed. In
silico prediction of pathogenicity for novel missense variants
was performed using Polyphen2, SIFT and Condel.w26 w27 25 A
variant was predicted to be pathogenic if classiﬁed as ‘damaging’
by SIFT and simultaneously ‘possibly’ or ‘probably damaging’
by Polyphen2, or if predicted to be damaging by Condel.
Summary statistics for genotype–phenotype associations
R (V.3.0.0) and SPSS (V.22.0.0.0, IBM Corp.) were used for the
analyses. Clinical phenotype data are presented as frequency
(and percentage) for non-continuous variables and mean±SD or
median and IQR for continuous variables where appropriate.
Normally distributed continuous variables were compared using
unpaired two-tailed Student’s t test. Multiple groups were com-
pared using analysis of variance. Categorical variables were com-
pared using χ2 or Fisher exact tests. When appropriate,
non-parametric tests were used.
Group comparisons were made for the prevalence and sever-
ity of each phenotypic trait (at baseline and ﬁnal follow-up) in
patients with and without a rare variant in one or more of the
eight most common SP genes (MYH7, MYBPC3, TNNI3,
TNNT2, MYL2, MYL3, ACTC1 and TPM1). We also compared
the prevalence and severity of each phenotypic trait in patients
carrying only one versus more than one variant in SP genes.
The same comparisons were made for the presence and absence
of rare variation in non-SP genes in the whole cohort and in the
subgroup of individuals with a disease-causing SP gene
mutation.
Multiple testing correction strategy
For each trait of interest we tested the effect of variants in eight
SP genes and 28 non-SP genes. Therefore, a nominal p value of
0.05 was not appropriate. In addition, the Bonferroni correction
for the number of phenotypes multiplied by the number of
genes is too stringent because it tests the global null of no asso-
ciation between any pair of gene/trait. We therefore took an
intermediate approach, correcting the analysis of each pheno-
type for the number of gene tests. For SP genes, we performed
nine tests (one per SP gene, plus an additional test for all SP
mutations combined). Therefore, we used p<0.0056, which is
0.05/9. For non-SP genes, we corrected for 28 tests, which
translates into p<0.0018=0.05/28. Data on associations that
did not fulﬁl these thresholds but met a nominal p value of
<0.05 are presented in the Results section and online supple-
mentary ﬁles.
Survival analysis
Deﬁnition of endpoints in the survival analyses was as previ-
ously described.23 Survival from cardiovascular death (a com-
posite of SCD and death from heart failure or stroke) and SCD
or equivalent (appropriate implantable cardioverter-deﬁbrillator
(ICD) shock) was modelled using Kaplan–Meier analysis and
log-rank test from the ﬁrst clinical evaluation at The Heart
Hospital and from birth.
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RESULTS
Study population
In all, 874 unrelated and consecutive patients with HCM were
studied. Mean follow-up time was 4.8±3.5 years (0–16.8 years).
Table 1 summarises the demographic and clinical characteristics
of the patients at initial evaluation and their outcomes.
SP genes variants
Overall, 383 patients (43.8%) had 265 distinct rare (minor
allele frequency ≤0.2%) variants in one or more the eight SP
genes most commonly associated with HCM (MYH7, MYBPC3,
TNNT2, TNNI3, MYL2, MYL3, ACTC1 and TPM1) (table 2 and
see online supplementary table S1). A total of 142 (53.5%) of
Table 1 Demographic and clinical characteristics of the study cohort
Frequency (percentage) or
mean±SD (range) or median (IQR)
Demographics
Age at initial evaluation (years) 49.6±15.4 (6–87)
Male 590/874 (67.8%)
Ethnicity
Caucasian 622 (71.2%)
Indian and other Asian 68 (7.8%)
African/Caribbean 39 (4.5%)
Chinese 6 (0.7%)
Other 20 (2.3%)
Not reported 119 (13.6%)
Presentation
Family history of HCM 226/853 (26.5%)
Family history of SCD 182/872 (20.9%)
NYHA class III or IV 100/850 (11.8%)
Syncope 140/856 (16.4%)
Chest pain 205/854 (24.0%)
Initial ECG
Atrial fibrillation 43/874 (4.9%)
PR interval (ms) 174.8±32.4 (108–320)
QRS duration (ms) 101.0±25.5 (64–238)
Initial CPEX
SBP rest (mm Hg) 128.8±21.0 (80–210)
SBP response to exercise (mmHg) 48.5±24.2 (-5–150)
Abnormal SBP response to exercise 92/662 (13.9%)
Initial echocardiography
Maximal LV wall thickness (mm) 18.5±4.4 (9–38)
Severe LVH (≥30 mm) 17/601 (2.8%)
Right ventricular hypertrophy (>5 mm) 184/864 (21.3%)
Asymmetric septal hypertrophy pattern 643/850 (75.6%)
Left atrial diameter (mm) 44.0±7.5 (18–90)
LV end-diastolic diameter (mm) 45.9±5.9 (29–65)
LV dilatation (>55 mm) 38/851 (4.5%)
LV end-systolic diameter (mm) 28.5±5.6 (9–50)
Fractional shortening (%) 38.3±8.2 (16–70)
Systolic dysfunction (≤25% FS) 29/829 (3.5%)
E wave deceleration time (ms) 221.0 (184–268)
Mitral regurgitation—moderate/severe 163/851 (19.2%)
Peak LVOT gradient (mm Hg) 12.0 (4.0–60.0)
LVOT gradient >30 mm Hg 328/812 (40.4%)
NSVT—Holter 127/566 (22.4%)
Follow-up
New-onset atrial fibrillation 216/874 (24.7%)
Implantable cardioverter-defibrillator 177/874 (20.3%)
Myectomy 130/874 (14.9%)
Alcohol septal ablation 46/874 (5.3%)
Myectomy and/or alcohol septal ablation and/or pacemaker implantation for LVOT gradient reduction 182/874 (20.8%)
Cardiovascular death 25/874 (2.9%)
SCD 16/874 (1.8%)
Total N=874.
CPEX, cardiopulmonary exercise test; FS, fractional shortening; HCM, hypertrophic cardiomyopathy; LVH, LV hypertrophy; LVOT, LV outflow tract; NSVT, non-sustained ventricular
tachycardia; NYHA, New York Heart Association; SBP, systolic blood pressure; SCD, sudden cardiac death.
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these rare variants were published previously as disease-causing
mutations; 44 (16.6%) were novel missense variants predicted
in silico to be pathogenic and 40 (15%) were novel potential
loss-of-function variants. In all, 37 patients (4.2%) carried mul-
tiple candidate variants in these eight SP genes.
Non-SP gene variants
In all, 114 distinct rare desmosomal protein gene variants were
present in 122 (14.0%) patients; 192 rare ion-channel disease
gene variants were present in 196 patients (22.4%). A total of
29 (25.4%) of the desmosomal variants and 38 (19.8%) of the
ion-channel variants were published previously. A further 74
(24.2%) of these non-sarcomere variants were novel missense
variants predicted in silico to be pathogenic and 20 (6.5%) were
potential loss-of-function variants. In all, 122 patients (43.0%
of 284) with these non-SP variants also carried a SP variant.
Genotype–phenotype associations
Genotype–phenotype associations signiﬁcant at the deﬁned
stringent thresholds are summarised in ﬁgures 1–3 and table 3.
A complete list of p values signiﬁcant at p<0.05 for all pairs of
traits/genes is provided in table 4 for non-SP genes and online
supplementary table S2 for SP and related genes. Online supple-
mentary table S3 summarises the associations for non-SP genes
presented in tables 3 and 4, analysed within the subcohort of
sarcomere-positive individuals only.
Effect of mutations in sarcomere genes
Patients with at least one variant in one of the eight main sarcomere
genes were younger at diagnosis and had a higher frequency of a
family history of HCM or SCD compared with those without sarco-
mere variants. Patients with SP mutations were more likely to have
asymmetric septal hypertrophy than apical or concentric patterns
and had greater MLVWT. The prevalence of male sex was lower in
sarcomere-positive individuals (62.4% vs 72.0%, p=0.00213); these
individuals were also more likely to have an ICD implanted. Patients
with sarcomere mutations had a lower resting systolic blood pressure
(SBP) (123.1±19.2 vs 133.7±21.3 mmHg, p=1.54×10−9) and a
lower SBP response to exercise (44.1±21.5 vs 52.2±26.9 mmHg,
p=7.61×10−5).
Similar and additional associations were observed when indi-
vidual SP genes were considered (table 3 and see online
supplementary table S2).
The proportion of cardiovascular deaths during follow-up
was higher in patients with at least one variant in one of the
eight main SP genes. The same was true for sudden death/ICD
discharge (ﬁgure 2 and 3).
Patients with multiple SP gene variants
Patients who carried more than one sarcomere variant had an
increased prevalence of syncope when compared with individuals
with only one sarcomere variant (35.1% vs 16.6%; 13/37 vs 56/
337, p=0.012). SBP response to exercise was lower in individuals
with multiple sarcomere variants compared with a single variant
(36.5±21.9 vs 45.1±21.2 mmHg, p=0.012) and there was a
higher proportion of patients with an abnormal blood pressure
response to exercise (10/29 vs 39/276; 34.5% vs 14.1%, p=0.010).
Associations with rare variants in desmosomal and
ion-channel genes
A total of 71 patients carried rare ANK2 variants (of these, 36
also carried SP variants). At a signiﬁcance threshold of
Table 2 Prevalence of rare variants (minor allele frequency
≤0.2%) in the eight main sarcomere genes
Gene
Number of
cases
Percentage of
sarcomere-positive
individuals (N=383)
Percentage of
the total cohort
(N=874)
ACTC1 3 0.8 0.3
MYBPC3 191 49.9 21.9
MYH7 99 25.9 11.3
MYL2 6 1.6 0.7
MYL3 4 1.0 0.5
TNNI3 15 3.9 1.7
TNNT2 20 5.2 2.3
TPM1 8 2.1 0.9
Multiple 37 9.7 4.2
Total 383 100 43.8
The number and proportion of individuals for each individual gene excludes patients
carrying more than one variant who are grouped under ‘multiple’.
Figure 1 Comparison between sarcomere gene mutation-positive and
-negative patients. (A) Age at initial evaluation (45.78±14.65 vs 53.05
±14.94 years). (B) Family history of hypertrophic cardiomyopathy
(HCM). (C) Family history of sudden cardiac death (SCD). (D)
Hypertrophy pattern. (E) Maximum wall thickness (18.83±4.42 vs 18.12
±4.08 mm). (F) Implanted implantable cardioverter-deﬁbrillators (ICDs).
Key: 0: sarcomere-negative; 1: sarcomere-positive. For B, C, E: red
colour and percentages indicate the individuals with the trait within
each genotype; for D light blue—asymmetric septal hypertrophy; red—
apical hypertrophy; green—concentric hypertrophy.
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p<0.0018, the proportion of patients with an MLVWT
≥30 mm was greater in carriers of an ANK2 rare variant (table
3). This association was still present when restraining the ana-
lyses to the subcohort of sarcomere-positive individuals only
(see online supplementary table S3).
Additional genotype–phenotype correlations were identiﬁed
at a less stringent p<0.05. These are listed in table 4, and
include an increased mean MLVWT in ANK2 variant carriers.
DISCUSSION
In this study of a large consecutive cohort of HCM probands
screened with high-throughput sequencing, we have detected a
class effect of SP gene variants on the HCM phenotype and
identiﬁed novel associations with mutations in individual SP
genes. We also demonstrated evidence of an association between
non-SP genes and disease expression that could explain some of
the characteristic clinical heterogeneity of HCM.
Inﬂuence of sarcomeric variation on phenotype
The presence of any sarcomere variant was associated with an
asymmetric septal hypertrophy pattern, younger age at presenta-
tion, family history of HCM and SCD and female gender. This
study also shows that patients with SP variants had higher car-
diovascular and sudden death-related mortality during
follow-up. Patients with more than one SP variant had more
Figure 3 Kaplan–Meier cumulative incidence curves for sudden
cardiac death/aborted sudden cardiac death, comparing
sarcomere-positive and sarcomere-negative individuals, modelled for
(A): follow-up from ﬁrst evaluation (years), log-rank test p value=0.039
(HR 2.89; 95% CI 1.01 to 8.33) and (B): time from birth (years),
log-rank test p value=0.028 (HR 3.44; 95% CI 1.19 to 9.92) . The Y
axis values indicate proportions.
Figure 2 Kaplan–Meier cumulative incidence curves for cardiovascular
death (see Methods section), comparing sarcomere-positive and
sarcomere-negative individuals, modelled for (A): follow-up from ﬁrst
evaluation (years), log-rank test p value=0.012 (HR 2.81; 95% CI 1.21 to
6.51) and (B): time from birth (years), log-rank test p value=0.001 (HR
3.99; 95% CI 1.71 to 9.36). The Y axis values indicate proportions.
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SCD risk markers, consistent with the suggestion in previously
published series of a gene dose effect.13 26–28 However, the low
number of outcome events during follow-up may have biased
the survival analysis and precluded an analysis of other associa-
tions, including the effect of carrying multiple compared with
single variants. The survival from birth is provided for compari-
son with the published literature but also introduces an inherent
survivor bias. With regard to individual SP genes, we demon-
strate a number of novel associations that provide evidence for
mutation speciﬁc effects on clinical phenotype and prognosis.
Modiﬁer effect of non-sarcomere variants
The data in this study suggest that rare ANK2 variants are asso-
ciated with severe LV hypertrophy. ANK2, or ankyrin B, stabi-
lises membrane ion-channels in cardiomyocytes and mutations
in the gene cause long QT syndrome 4, ventricular arrhythmias
and sinus node disease.29 30 We are unaware of any link
between ANK2 expression and changes in LV morphology, but
as ankyrins interact with proteins that inﬂuence calcium homeo-
stasis and ß-adrenergic signalling, it is conceivable that they
eventually affect the cellular phenotype that results from a
primary SP gene variant. The strength of the statistical associ-
ation (p=0.0005) exceeds the requirement of a Bonferroni cor-
rection for the number of tested genes (36 independent tests),
but further replication in independent cohorts will be necessary
to conﬁrm these results.
In addition to the association with ANK2 variation, we
detected a number of associations at lower statistical signiﬁcance
with variation in other non-SP genes. Patients with SCN5A rare
variants were more likely to have left atria enlargement at their
last evaluation. A link between SCN5A disruption and
TGF-β1-mediated ﬁbrosis has recently been demonstrated in a
murine model of sinus node diseasew28 and it is possible that
SCN5A variants inﬂuence the pro-ﬁbrotic milieu associated with
SP mutations. SCN5A rare variation was also associated with a
higher proportion of LV outﬂow tract obstruction. Individuals
with PLN rare variants were more likely to have NSVT, which is
interesting considering the recently described arrhythmogenic
risk of a founder PLN mutation.w29 As for the association with
ANK2, replication of these ﬁndings is required.
Table 3 Genotype–phenotype associations for individual sarcomeric and related protein genes and non-sarcomere protein (SP) genes meeting
the predefined statistical thresholds for multiple testing.
Phenotype Gene
Frequency or mean±SD
Rare variant present
Frequency or mean±SD
Rare variant absent p Value
Age at initial evaluation (years) MYBPC3 45.5±14.4 51.0±15.5 8.97×10−6
MYH7 43.9±15.4 50.5±15.2 1.91×10−5
Family history of HCM MYBPC3 40.4% (86/213) 21.9% (140/640) 2.7×10−7
MYH7 47.4% (54/114) 23.4% (173/740) 3.06×10−7
Family history of SCD MYBPC3 28.7% (62/216) 18.3% (120/656) 0.001
MYH7 31.6% (37/117) 19.2% (145/775) 0.003
ASH pattern MYBPC3 88.0% (184/209) 71.6% (459/641) 3.75×10−6
MYH7 89.2% (99/111) 73.6% (544/739) 0.001
MLVWT (mm) MYBPC3 19.4±4.7 18.2±4.2 0.0005
MLVWT ≥30 mm ANK2 12.5% (6/48) 2% (11/553) 0.0005
LV end-diastolic diameter (mm) MYBPC3 44.8±5.5 46.3±6.0 0.00089
LV end-systolic diameter (mm) MYBPC3 27.4±6.0 28.8±5.4 0.005
Right ventricular hypertrophy TNNI3 50% (10/20) 21.6% (174/806) 0.004
SBP response to exercise (mmHg) MYH7 36.6±19.9 50.2±24.4 5.49×10−6
Abnormal SBP response to exercise TNNT2 40.9% (9/22) 13.0% (83/640) 0.002
Myectomy and/or alcohol septal ablation
and/or pacemaker implantation for gradient reduction
MYBPC3 (splicing variants) 43.1% (22/51) 20.0% (160/799) 3.0×10−4
LVOTO (>30 mm Hg) TNNI3 10.0% (2/20) 41.2% (326/792) 0.005
p Values reflect the comparison for proportions or means between the group of patients with versus the group of patients without a rare variant in a given gene (p value thresholds of
<0.0056 for SP genes and <0.0018 for non-SP genes).
ASH, asymmetric septal hypertrophy; SBP, systolic blood pressure; HCM, hypertrophic cardiomyopathy; LVOTO, LV outflow tract obstruction; MLVWT, maximum LV wall thickness; SCD,
sudden cardiac death.
Table 4 Genotype–phenotype associations for non-sarcomeric protein genes not meeting the predefined statistical thresholds for multiple
testing
Phenotype Gene Frequency or mean±SD—Variant present Frequency or mean±SD—Variant absent p Value
LA diameter at last follow-up (mm) SCN5A 46.9±5.4 44.3±7.5 0.04
LVOTO (>30 mm Hg) SCN5A 57.5% (23/40) 39.5% (305/772) 0.03
Ion-channel 49.2% (89/181) 37.9% (239/631) 0.006
MLVWT (mm) ANK2 19.7±5.6 18.4±4.2 0.02
E/e0 ratio CASQ2 16.4±7.1 11.4±5.9 0.02
NSVT PLN 100% (3/3) 22.1% (124/562) 0.01
p Values reflect the comparison for proportions or means between patients with and without a rare variant in a given gene.
E to é ratio, ratio between the maximal velocity of the E wave from the pulsed wave Doppler of the transmitral flow and the maximal velocity of the e0 wave of tissue Doppler at the
mitral annulus; LA, left atria; LVOTO, LV outflow tract obstruction; MLVWT, maximal LV wall thickness; NSVT, non-sustained ventricular tachycardia.
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Clinical implications
If genetic variation is to become a clinically relevant biomarker,
it is essential that there is a clear understanding of genotype–
phenotype relationships. The associations between sarcomere
gene variants and the broad phenotype examined in this study
contribute to this understanding and, if conﬁrmed in other
populations, could inform the counselling of patients and rela-
tives who are contemplating predictive genetic testing. The dem-
onstration that non-sarcomeric variants may inﬂuence disease
expression is an illustration of the complexity that underlies the
biology of this disease. New models that incorporate a broad
genetic proﬁle and deep clinical phenotyping are necessary to
test the role of mutation analysis in prognostic models.
Key messages
What is known on this subject?
In up to 50% of cases, hypertrophic cardiomyopathy is caused
by mutations in genes coding for sarcomere or
sarcomere-related genes, but the often dramatic variation in
clinical phenotypes caused by the same or similar mutations
remains largely unexplained.
What might this study add?
This study presents novel genotype–phenotype associations in a
large cohort of 874 patients using high-throughput genetic
sequencing. We describe a strong class effect for sarcomeric
protein variants on clinical presentation, LV morphology and
survival. For the ﬁrst time, a modiﬁer effect of rare variants in
non-sarcomeric genes associated with other forms of
cardiomyopathy and arrhythmia syndromes is demonstrated.
How might this impact on clinical practice?
These are novel ﬁndings which suggest new and testable
insights on the biology and pathophysiology of the disease that
might eventually have important clinical implications for
counselling of patients and risk prediction models.
Contributors LRL: conception and design of the study, analysis and interpretation
of data, drafting of the manuscript, and ﬁnal approval of the manuscript submitted;
PS, WJM, PME and VP: conception and design of the study, analysis and
interpretation of data, revising the manuscript critically for important intellectual
content, and ﬁnal approval of the manuscript submitted; OPG, MH, CO’M, HCT, CD,
SJ and LM: analysis and interpretation of data, revising the manuscript critically for
important intellectual content, and ﬁnal approval of the manuscript submitted.
Funding LRL was supported by a grant from the Gulbenkian Doctoral Programme
for Advanced Medical Education, sponsored by Fundação Calouste Gulbenkian,
Fundação Champalimaud, Ministério da Saúde and Fundação para a Ciência e
Tecnologia, Portugal. OPG received research support from the British Heart
Foundation. This work, including support for Chrysoula Dalageorgou, was
undertaken at UCLH/UCL who received a proportion of funding from the Department
of Health’s NIHR Biomedical Research Centres funding scheme. LM received funding
from the grant: FIS 2011: PI11/02604. Instituto de Salud Carlos III, Madrid, Spain.
VP is partly supported by the National Institute of Health Research (NIHR)
Biomedical Research Centre based at Moorﬁelds Eye Hospital NHS Foundation Trust
and UCL Institute of Ophthalmology.
Competing interests LM is a shareholder of Health in Code SL.
Ethics approval University College London (UCL)/UCL Hospitals (UCLH) Joint
Research Ethics Committee.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
REFERENCES
1 Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004;
363:1881–91.
2 Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA Guideline for the Diagnosis
and Treatment of Hypertrophic Cardiomyopathy: a report of the American College
of Cardiology Foundation/American Heart Association Task Force on Practice
Guidelines. Developed in collaboration with the American Association for Thoracic
Surgery, American Society of Echocardiography, American Society of Nuclear
Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for
Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
J Am Coll Cardiol 2011;58:e212–60.
3 Charron P, Arad M, Arbustini E, et al. Genetic counselling and testing in
cardiomyopathies: a position statement of the European Society of Cardiology
Working Group on Myocardial and Pericardial Diseases. Eur Heart J
2010;31:2715–26.
4 Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after
20 years: clinical perspectives. J Am Coll Cardiol 2012;60:705–15.
5 Olivotto I, Girolami F, Ackerman MJ, et al. Myoﬁlament protein gene mutation
screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin
Proc 2008;83:630–8.
6 Lopes LR, Rahman MS, Elliott PM. A systematic review and meta-analysis of
genotype-phenotype associations in patients with hypertrophic cardiomyopathy
caused by sarcomeric protein mutations. Heart 2013;99:1800–11.
7 Watkins H. Genotype: phenotype correlations in hypertrophic cardiomyopathy. Eur
Heart J 1998;19:10–2.
8 Ackerman MJ, VanDriest SL, Ommen SR, et al. Prevalence and age-dependence of
malignant mutations in the beta-myosin heavy chain and troponin T genes in
hypertrophic cardiomyopathy: a comprehensive outpatient perspective. J Am Coll
Cardiol 2002;39:2042–8.
9 Van Driest SL, Ackerman MJ, Ommen SR, et al. Prevalence and severity of
“benign” mutations in the beta-myosin heavy chain, cardiac troponin T, and
alpha-tropomyosin genes in hypertrophic cardiomyopathy. Circulation
2002;106:3085–90.
10 Charron P, Dubourg O, Desnos M, et al. Genotype-phenotype correlations in
familial hypertrophic cardiomyopathy. A comparison between mutations in the
cardiac protein-C and the beta-myosin heavy chain genes. Eur Heart J
1998;19:139–45.
11 Charron P, Dubourg O, Desnos M, et al. Clinical features and prognostic
implications of familial hypertrophic cardiomyopathy related to the cardiac
myosin-binding protein C gene. Circulation 1998;97:2230–6.
12 Moolman JC, Corﬁeld VA, Posen B, et al. Sudden death due to troponin T
mutations. J Am Coll Cardiol 1997;29:549–55.
13 Van Driest SL, Vasile VC, Ommen SR, et al. Myosin binding protein C mutations
and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol
2004;44:1903–10.
14 Pasquale F, Syrris P, Kaski JP, et al. Long-term outcomes in hypertrophic
cardiomyopathy caused by mutations in the cardiac troponin T gene. Circ
Cardiovasc Genet 2012;5:10–17.
15 Page SP, Kounas S, Syrris P, et al. Cardiac myosin binding protein-C mutations
in families with hypertrophic cardiomyopathy: disease expression in relation to
age, gender, and long term outcome. Circ Cardiovasc Genet 2012;
5:156–66.
16 Van Driest SL, Jaeger MA, Ommen SR, et al. Comprehensive analysis of the
beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic
cardiomyopathy. J Am Coll Cardiol 2004;44:602–10.
17 Daw EW, Chen SN, Czernuszewicz G, et al. Genome-wide mapping of modiﬁer
chromosomal loci for human hypertrophic cardiomyopathy. Hum Mol Genet
2007;16:2463–71.
18 Kolder IC, Michels M, Christiaans I, et al. The role of renin-angiotensin-aldosterone
system polymorphisms in phenotypic expression of MYBPC3-related hypertrophic
cardiomyopathy. Eur J Hum Genet 2012;20:1071–7.
19 Lopes LR, Zekavati A, Syrris P, et al. Genetic complexity in hypertrophic
cardiomyopathy revealed by high-throughput sequencing. J Med Genet
2013;50:228–39.
20 Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic
cardiomyopathy: identiﬁcation of high risk patients. J Am Coll Cardiol
2000;36:2212–8.
21 Elliott P, Andersson B, Arbustini E, et al. Classiﬁcation of the cardiomyopathies:
a position statement from the European Society Of Cardiology Working Group on
Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270–6.
Lopes LR, et al. Heart 2014;0:1–8. doi:10.1136/heartjnl-2014-306387 7
Heart failure and cardiomyopathies
group.bmj.com on January 29, 2015 - Published by http://heart.bmj.com/Downloaded from 
22 McKenna WJ, Spirito P, Desnos M, et al. Experience from clinical genetics in
hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members
of affected families. Heart 1997;77:130–2.
23 O’Mahony C, Tome-Esteban M, Lambiase PD, et al. A validation study of the 2003
American College of Cardiology/European Society of Cardiology and 2011 American
College of Cardiology Foundation/American Heart Association risk stratiﬁcation and
treatment algorithms for sudden cardiac death in patients with hypertrophic
cardiomyopathy. Heart 2013;99:534–41.
24 DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery
and genotyping using next-generation DNA sequencing data. Nat Genet 2011;43:491–8.
25 Gonzalez-Perez A, Lopez-Bigas N. Improving the assessment of the outcome of
nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum
Genet 2011;88:440–9.
26 Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic
determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med
2008;5:158–68.
27 Girolami F, Ho CY, Semsarian C, et al. Clinical features and outcome of
hypertrophic cardiomyopathy associated with triple sarcomere protein gene
mutations. J Am Coll Cardiol 2010;55:1444–53.
28 Bauce B, Nava A, Beffagna G, et al. Multiple mutations in desmosomal proteins
encoding genes in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart
Rhythm 2010;7:22–9.
29 Webster G, Berul CI. An update on channelopathies: from mechanisms to
management. Circulation 2013;127:126–40.
30 Hashemi SM, Hund TJ, Mohler PJ. Cardiac ankyrins in health and disease. J Mol
Cell Cardiol 2009;47:203–9.
8 Lopes LR, et al. Heart 2014;0:1–8. doi:10.1136/heartjnl-2014-306387
Heart failure and cardiomyopathies
group.bmj.com on January 29, 2015 - Published by http://heart.bmj.com/Downloaded from 
cardiomyopathy
sequencing in patients with hypertrophic
demonstrated by high-throughput 
phenotype associations−Novel genotype
Elliott
Lorenzo Monserrat, William J McKenna, Vincent Plagnol and Perry M 
Hubank,Hak Chiaw Tang, Chrysoula Dalageorgou, Sharon Jenkins, Mike 
Luis R Lopes, Petros Syrris, Oliver P Guttmann, Constantinos O'Mahony,
 published online October 28, 2014Heart 
 http://heart.bmj.com/content/early/2014/10/28/heartjnl-2014-306387
Updated information and services can be found at: 
These include:
Material
Supplementary
 DC1.html
http://heart.bmj.com/content/suppl/2014/10/28/heartjnl-2014-306387.
Supplementary material can be found at: 
References
 #BIBL
http://heart.bmj.com/content/early/2014/10/28/heartjnl-2014-306387
This article cites 30 articles, 13 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (271)Hypertrophic cardiomyopathy
 (8076)Drugs: cardiovascular system
 (117)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on January 29, 2015 - Published by http://heart.bmj.com/Downloaded from 
